We are investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030.
At least two investors have already expressed extreme disappointment in the sale price on SeekingAlpha.
If you remain a Monogram shareholder and have concerns about the proposed sale, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On July 14, 2025, Monogram announced that it had agreed to be sold to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable CVR entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030.
At least two investors have expressed disappointment in the sale price on SeekingAlpha with one investor complaining, “Too cheap!,” and another responding that “I am not very happy about it either.”
“We are investigating whether the Monogram Board of Directors acted in the best interests of Monogram shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Monogram shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”